These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292 [TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results. Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320 [TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study. Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817 [TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764 [TBL] [Abstract][Full Text] [Related]
28. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes. Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082 [TBL] [Abstract][Full Text] [Related]
29. VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration. Veloso CE; de Almeida LN; Recchia FM; Pelayes D; Nehemy MB Ophthalmic Res; 2014; 51(1):1-8. PubMed ID: 24157918 [TBL] [Abstract][Full Text] [Related]
30. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Gupta B; Adewoyin T; Patel SK; Sivaprasad S Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Roller AB; Folk JC; Patel NM; Boldt HC; Russell SR; Abramoff MD; Mahajan VB Retina; 2011 Oct; 31(9):1848-55. PubMed ID: 21610563 [TBL] [Abstract][Full Text] [Related]
32. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis. Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458 [TBL] [Abstract][Full Text] [Related]
33. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959 [TBL] [Abstract][Full Text] [Related]
34. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy. Shienbaum G; Garcia Filho CA; Flynn HW; Nunes RP; Smiddy WE; Rosenfeld PJ Am J Ophthalmol; 2013 Jun; 155(6):1009-13. PubMed ID: 23465269 [TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML Retina; 2007; 27(4):439-44. PubMed ID: 17420695 [TBL] [Abstract][Full Text] [Related]
36. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. Lad EM; Hammill BG; Qualls LG; Wang F; Cousins SW; Curtis LH Am J Ophthalmol; 2014 Sep; 158(3):537-43.e2. PubMed ID: 24857687 [TBL] [Abstract][Full Text] [Related]
37. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500 [TBL] [Abstract][Full Text] [Related]
38. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration. Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871 [TBL] [Abstract][Full Text] [Related]
39. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121 [TBL] [Abstract][Full Text] [Related]
40. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA; Retina; 2008; 28(10):1387-94. PubMed ID: 18827735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]